Figure 1.

Study outcomes, Intent-to-Treat analysis (N = 1506) separately by clinical presentation (ACS, chronic coronary syndrome). (A) Safety outcomes; (B) Efficacy outcomes; and (C) Net clinical benefit. ACS, acute coronary syndrome; ARC, academic research consortium; CCS, chronic coronary syndrome; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; ICH, intracranial haemorrhage; ISTH, International Society on Thrombosis and Haemostasis; ITT, intent-to-treat; MI, myocardial infarction; NA, not available; SEE, systemic embolic event; VKA, vitamin K antagonist. P-value of interaction results are based on a Cox model with treatment group, the three stratification factors: geographic region, requirement for dose adjustment and clinical presentation, and the interaction term between clinical presentation and treatment.